NovoCure
NVCR
244 hedge funds and large institutions have $1.19B invested in NovoCure in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 79 reducing their positions, and 45 closing their positions.
355% more call options, than puts
Call options by funds: $20.4M | Put options by funds: $4.49M
8% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 79
7% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 45
1% more funds holding
Funds holding: 242 → 244 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.69% less ownership
Funds ownership: 84.73% → 82.04% (-2.7%)
30% less capital invested
Capital invested by funds: $1.68B → $1.19B (-$496M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$36.6M |
| 2 |
Millennium Management
New York
|
+$9.2M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.1M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$7.21M |
| 5 |
AG
Algert Global
San Francisco,
California
|
+$7.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$58.6M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$40.4M |
| 3 |
DM
Deerfield Management
New York
|
-$14.7M |
| 4 |
GIP
Granite Investment Partners
El Segundo,
California
|
-$10.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$8.96M |
NVCR Hedge Fund Activity: Q3 2025 in Review
244 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2025, worth a combined $1.19B — down 30% from $1.68B a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new NVCR positions and 45 closed out — a net gain of 3 holders — while 85 added to existing stakes and 79 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $36.6M. The largest seller was Capital World Investors, cutting an estimated $58.6M.
- 244 institutional investors held NovoCure (NVCR) as of Q3 2025, up from 242 in Q2 2025.
- Funds reported $1.19B of NovoCure stock for Q3 2025, down 30% quarter-over-quarter.
- 48 funds opened new NovoCure positions in Q3 2025 and 45 closed out, a net change of +3 holders.
- The largest NovoCure buyer in Q3 2025 was Soleus Capital Management, an estimated $36.6M added.
- The largest NovoCure seller in Q3 2025 was Capital World Investors, an estimated $58.6M sold.
Based on aggregated 13F filings for Q3 2025.